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AbstrACt
Objectives To characterise the comorbidities of heart 
failure (HF) in men and women, to explore their clustering 
into multimorbidity patterns, and to measure the impact 
of such patterns on the risk of hospitalisation and 
mortality.
Design Observational retrospective population study 
based on electronic health records.
setting EpiChron Cohort (Aragón, Spain).
Participants All the primary and hospital care patients of 
the EpiChron Cohort with a diagnosis of HF on 1 January 
2011 (ie, 8488 women and 6182 men). We analysed all the 
chronic diseases registered in patients’ electronic health 
records until 31 December 2011.
Primary outcome We performed an exploratory factor 
analysis to identify the multimorbidity patterns in men 
and women, and logistic and Cox proportional- hazards 
regressions to investigate the association between the 
patterns and the risk of hospitalisation in 2012, and of 
3- year mortality.
results Almost all HF patients (98%) had multimorbidity, 
with an average of 7.8 chronic diseases per patient. We 
identified six different multimorbidity patterns, named 
cardiovascular, neurovascular, coronary, metabolic, 
degenerative and respiratory. The most prevalent were the 
degenerative (64.0%) and cardiovascular (29.9%) patterns 
in women, and the metabolic (49.3%) and cardiovascular 
(43.2%) patterns in men. Every pattern was associated 
with higher hospitalisation risks; and the cardiovascular, 
neurovascular and respiratory patterns significantly 
increased the likelihood of 3- year mortality.
Conclusions Multimorbidity is the norm rather than 
the exception in patients with heart failure, whose 
comorbidities tend to cluster together beyond simple 
chance in the form of multimorbidity patterns that have 
different impact on health outcomes. This knowledge 
could be useful to better understand common 
pathophysiological pathways underlying this condition 
and its comorbidities, and the factors influencing the 
prognosis of men and women with HF. Further large 
scale longitudinal studies are encouraged to confirm the 
existence of these patterns as well as their differential 
impact on health outcomes.
IntrODuCtIOn
Improvements in diagnostic and thera-
peutic procedures have decreased heart 
failure (HF) mortality rates, transforming 
this previously life- threatening condition 
into a chronic disease with a high burden 
of comorbidity, as confirmed by European 
HF registries.1 HF patients are complex and 
present different phenotypes depending on 
age, sex, comorbidity and pathophysiological 
and prognostic aspects.2 Both cardiovascular 
and non- cardiovascular comorbidities are 
determining factors in the differentiation of 
these phenotypes and their impact on health 
outcomes. In fact, HF patients with non- 
cardiovascular comorbidities show increased 
disease burden, severity, risk of hospitalisa-
tion and death.3 4
strengths and limitations of this study
 ► This is a large- scale population- based study that in-
cluded the primary and hospital care patients of the 
reference population with a diagnosis of HF.
 ► The data in the cohort continuously underwent qual-
ity control check- ups to ensure its accuracy and re-
liability for research purposes.
 ► The cross- sectional characterisation of the multi-
morbidity patterns made it impossible to understand 
the chronological relationship between the different 
risk factors and chronic diseases.
 ► Diagnoses were extracted from electronic health re-
cords that were not originally designed for research, 
thus leading to a potential over or under- reporting of 
specific diseases.
 ► The estimation of the effect of multimorbidity pat-
terns on health outcomes did not consider the po-
tential confounding role of socioeconomic factors or 
clinical parameters, like the ejection fraction, which 
were not available in the study cohort.
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Recent studies have examined the most prevalent 
comorbidities in HF patients and their prognostic 
impact on mortality rates and hospital readmissions.2 5 6 
However, although the clustering of chronic diseases into 
multimorbidity patterns has already been demonstrated 
in the general population,7 most studies still focus on 
isolated comorbidities, without considering the interre-
lations among them. Some of the few studies addressing 
multimorbidity in HF patients restrict their analyses to 
the most frequently co- occurring combinations of two 
or three comorbidities,8 while others are conducted in 
relatively small samples.9 Moreover, the methodological 
approaches in these studies in terms of data sources, 
studied comorbidities and statistical techniques vary 
considerably.3 8–10 Thus, there is still a need to perform 
studies on real patients from primary care, where multi-
morbidity is most frequently dealt with, and to address 
the sex/gender perspective of this disease and its 
comorbidities.
The Academy of Medical Sciences recently highlighted 
the importance of investigating which multimorbidity 
patterns cause the greatest burden of disease, and the 
determinants of the most common clusters of condi-
tions.11 Improving our knowledge on the systematic asso-
ciations among HF comorbidities is of great interest, as 
some of them are known to share common biological 
and socioeconomic risk factors on which prevention 
strategies could be based. Furthermore, the identifi-
cation and clinical characterisation of multimorbidity 
patterns in men and women with HF, and the study of 
their potential impact on negative health outcomes (eg, 
risk of death and hospitalisation) could shed light on 
new pathophysiological pathways. These pathways could 
help guide the development of clinical practice guide-
lines better adapted to patients with HF based on their 
sex and comorbidities.12
This large- scale population study based on electronic 
health records from real primary and hospital care 
patients aimed to characterise the comorbidities of HF in 
men and women, to explore their clustering into multi-
morbidity patterns, and to measure the impact of such 
patterns on negative health outcomes.
MethODs
Design and study population
We conducted a retrospective observational study based 
on the EpiChron Cohort, which links demographic, clin-
ical and health outcome- related information for all public 
health system users of the Spanish region of Aragón. A 
description of the cohort profile and of the data sources 
was published elsewhere.13 This cohort was conformed 
in 2011 and it included 1 253 292 people at baseline 
(approximately 95% of the total inhabitants of Aragón). 
For this study, we selected all patients with HF diagnosis 
in their primary or hospital electronic health records on 
1 January 2011 and followed them up for 3 years.
study variables
For each patient, we analysed demographic data (ie, 
age, sex, area of residence, immigration status), hospital 
admissions during 2012, all chronic condition diagnoses 
from primary and/or hospital care, and all- cause mortality 
until 31 December 2014. Diagnoses were extracted 
from the electronic health records of both primary and 
hospital care levels, and included all active episodes 
between 1 January 2011 and 31 December 2011, even if 
a healthcare professional had recorded them before the 
initial date. Diseases were originally coded according to 
the International Classification of Primary Care (ICPC) 
(in primary care settings) or the International Classi-
fication of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9- CM) (in hospital settings), and subsequently 
grouped into 260 mutually exclusive Expanded Diag-
nostic Clusters (EDCs) through the Johns Hopkins ACG 
System (version 11.0, The Johns Hopkins University, 
Baltimore, MD, US).14 We included every patient with 
the CAR05 EDC code, as well as the ICPC and ICD-9- CM 
codes for HF, and considered all 114 possible EDCs previ-
ously established as chronic by Salisbury et al15 for the 
analysis. Multimorbidity was defined as the presence of 
two or more EDCs from Salisbury’s list.
This study complies with the Declaration of Helsinki, 
and the Clinical Research Ethics Committee of Aragón 
(CEICA) approved the research protocol (PI18/082). 
The CEICA waived the requirement to obtain informed 
consent from patients since all the information was 
anonymised.
statistical analyses
All our analyses were stratified by sex. First, we performed 
a descriptive analysis of the demographic and clinical 
information of the population with HF. We compared 
means and frequencies using Student’s t- test and the chi- 
squared test, respectively, with their corresponding 95% 
confidence intervals.
Second, we applied an exploratory factor analysis to 
identify the existence of non- random associations among 
chronic diseases in men and women. To facilitate the 
epidemiological and clinical interpretation of the results, 
we only included in the analysis those chronic comorbid-
ities from Salisbury’s list with a prevalence ≥5% in each 
sex. The methodology followed was described elsewhere.7 
Briefly, EDCs were coded as binary variables (present/
absent), and a factor analysis based on a tetrachoric 
correlation matrix was performed to determine which 
diagnoses comprised each factor. We used the principal 
factor method for the extraction of the factors, and a 
scree plot in combination with clinical criteria to deter-
mine the number of factors to extract. The EDCs with 
factor scores≥0.25 within a pattern were considered to 
be part of that multimorbidity pattern, so that the same 
EDC could be present in more than one pattern. Model 
goodness- of- fit and sample adequacy were calculated 
through the proportions of cumulative variance and the 
Kaiser- Meyer- Olkin (KMO) parameter. After performing 
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the factor analysis, three clinical experts (FRL, CCS and 
APT) proposed and agreed on the denomination of the 
resulting patterns according to the most relevant diseases 
and those with the highest loading factor within each 
pattern. Individuals were subsequently assigned to one or 
more of the described patterns of multimorbidity if they 
had at least two of the diseases that comprised the pattern 
(in addition to HF), as described by Prados et al.7
Finally, we applied logistic and Cox proportional- 
hazards regressions to calculate the risk of having at least 
one hospitalisation during 2012 and of 3- year mortality, 
respectively, depending on the multimorbidity pattern 
suffered by the individual (compared with having no 
patterns). Patient age (continuous variable) and all the 
multimorbidity patterns were included as independent 
variables in the models. We used Kaplan- Meier survival 
curves to represent and compare survival rates of indi-
viduals with specific multimorbidity patterns, which were 
also used to test for the proportional hazard assumption.
We conducted all statistical analyses using STATA 
(Version 12.0, StataCorp LLC, College Sation, TX, US). 
Statistical significance was set at p<0.05.
Patient and public involvement
Patients and public were not involved in this study.
results
A total of 14 670 patients from the EpiChron Cohort 
had a HF diagnosis in 2011, representing around 1.1% 
of the total population of Aragón. The study population 
is described in table 1. Women predominated over men 
(57.9% vs 42.1%, p<0.001) and were older on average 
(79.9 vs 75.2 years, p<0.001), mainly due to a higher 
proportion of people aged ≥85 years. The cumulative 
mortality rate throughout the 3- year follow- up was higher 
in men than in women (36.5% vs 33.3 %, p<0.001), and 
the same pattern was observed for hospital admissions.
In our study, almost all patients with HF (98%) suffered 
from multimorbidity, with an average disease burden of 7.8 
chronic diseases per patient (HF included). These figures 
are higher than those observed in the reference cohort 
(38% and 1.7 chronic diseases/patient, respectively). The 
most prevalent HF comorbidities were similar in women 
and in men, and were hypertension (71.2% vs 65.0%), 
dyslipidemia (36.9% vs 37.6%), arthropathy (36.8% vs 
23.9%), cardiac arrhythmia (35.5% vs 42.6%) and diabetes 
(30.3% vs 32.3%). Except for hypertension, which was 
more frequent in women, cardiovascular comorbidities (ie, 
ischaemic heart disease and arrhythmias) as well as COPD, 
were more prevalent in men. Arthropathy, varicose veins 
of lower extremities, obesity, osteoporosis, dementia and 
depression were also highly prevalent in HF patients, espe-
cially in women.
We identified and described six multimorbidity patterns 
in women, which resulted from the factorial analysis, 
namely cardiovascular, respiratory, metabolic, coronary- 
ischaemic, degenerative and neurovascular patterns. Men 
only showed five patterns, which were similar to those 
observed in women, with the exception of the respiratory 
pattern. Tables 2 and 3 describe the compositions of the 
multimorbidity patterns in women and men, respectively. 
In women, these patterns explained up to 40.5% of the 
cumulative total variance, with a KMO of 0.753. In men, 
the patterns explained up to 37.3% of the cumulative 
total variance, with a KMO of 0.761.
A high proportion of the study population was assigned 
to these patterns, with prevalence rates ranging from 
13.5% (neurovascular) to 64.0% (degenerative) in 
women, and from 22.2% (neurovascular) to 49.3% (meta-
bolic) in men. The prevalence and impact on health 
outcomes of such multimorbidity patterns is described in 
table 4. In general, all the multimorbidity patterns were 
associated with an increased risk of hospitalisation during 
the following year (12%–86% increase) in both men and 
women compared with the absence of the pattern, except 
for the degenerative pattern in women. The cardiovas-
cular, neurovascular and respiratory patterns significantly 
increased the likelihood of 3- year mortality (45%–
74% increase) in both sexes. The Kaplan- Meier survival 
curves for the population with HF according to different 
multimorbidity patterns are presented in figure 1.
DIsCussIOn
Comorbidity of heart Failure
The higher morbidity burden found in our population 
with HF when compared with the general population of 
the EpiChron Cohort13 could probably be explained by 
the differences in their age and sex distributions (mean 
age of 77.9 vs 44.2 years, and 57.9% vs 50.5% of women, 
respectively). The fact that almost the entire population 
with HF suffered from multimorbidity (ie, at least one 
comorbidity in addition to HF) could be due in part to 
our operationalization of multimorbidity, whereby an 
exceptionally comprehensive list of chronic conditions 
was considered. Although most studies agree in defining 
multimorbidity as the co- occurrence of two or more 
chronic conditions, different classification systems are 
frequently used and the number of diseases considered 
can vary from 5 to 335 conditions among studies.16 17 
This lack of international consensus regarding the defini-
tion of multimorbidity hinders the comparison of results 
among studies, and the estimations of its prevalence and 
health impact.
In our study, ischaemic heart disease and arrhythmias 
were the most prevalent HF comorbidities in men, and 
hypertension was the most frequent in women, as previ-
ously described.1 The higher prevalence of COPD in men 
compared with women was probably due to the higher 
rates of smoking among Spanish men.18 While the esti-
mated prevalence of COPD in the general Spanish popu-
lation is 15% in men and 6% in women,19 these figures 
were almost doubled in our HF cohort, approaching the 
25.6% described in the EAHFE- COPD Study on acute 
HF patients.20 The higher COPD prevalence might be 
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Table 1 Demographic and clinical description of patients with heart failure (n=14 670)
Characteristics Women (n=8488) Men (n=6182) P value
Demographics
  Sex (%) 57.9 (57.1–58.7) 42.1 (41.3–42.9) <0.001
  Mean age (years) 79.9 (79.6–80.1) 75.2 (74.8–75.5) <0.001
  Age interval (%)
   ≤44 years 2.34 (2.02–2.67) 3.87 (3.39–4.35)
   45–64 years 6.03 (5.53–6.54) 13.2 (12.3–14.0)
   65–84 years 52.6 (51.5–53.6) 58.7 (57.4–59.9)
   ≥85 years 39.0 (38.0–40.1) 24.3 (23.2–25.3)
  Urban area (vs rural) (%) 55.7 (54.6–56.7) 52.3 (51.0–53.5) <0.001
  Immigrants (%) 0.95 (0.74–1.16) 1.38 (1.08–1.67) 0.017
Clinical information
  3- year all- cause mortality (%) 33.3 (32.3–34.3) 36.5 (35.3–37.7) <0.001
  Multimorbidity* (%) 98.2 (97.9–98.4) 97.7 (97.3–98.1) 0.068
  Mean number of diseases 7.77 (7.69–7.85) 7.87 (7.77–7.97) 0.114
  Prevalence of comorbidities (%)
   Hypertension 71.2 (70.2–72.1) 65.0 (63.8–66.2) <0.001
   Cardiac arrhythmia 35.5 (34.4–36.5) 42.6 (41.4–43.9) <0.001
   Disorders of lipid metabolism 36.9 (35.8–37.9) 37.6 (36.4–38.8) 0.388
   Arthropathy 36.8 (35.8–37.8) 23.9 (22.8–25.0) <0.001
   Diabetes 30.3 (29.4–31.3) 32.3 (31.2–33.5) 0.010
   Varicose veins of lower extremities 29.4 (28.4–30.4) 11.8 (11.0–12.6) <0.001
   Emphysema, chronic bronchitis, COPD 13.3 (12.6–14.0) 32.8 (31.6–34.0) <0.001
   Cardiovascular disorders, other 19.2 (18.4–20.0) 24.0 (22.9–25.0) <0.001
   Ischaemic heart disease (excluding AMI†) 15.3 (14.5–16.0) 24.6 (23.5–25.7) <0.001
   Obesity 20.3 (19.4–21.1) 17.6 (16.7–18.5) <0.001
   Depression 24.8 (23.8–25.7) 10.9 (10.1–11.7) <0.001
   Cataract, aphakia 19.7 (18.9–20.6) 16.9 (15.9–17.8) <0.001
   Surgical aftercare 15.8 (15.0–16.6) 19.3 (18.3–20.2) <0.001
   Cardiac valve disorders 17.0 (16.2–17.8) 17.5 (16.6–18.4) 0.394
   Iron deficiency, other deficiency anemias 17.3 (16.5–18.1) 15.6 (14.7–16.5) 0.007
   Osteoporosis 23.1 (22.2–24.0) 3.69 (3.22–4.16) <0.001
   Cerebrovascular disease 13.9 (13.2–14.7) 14.3 (13.4–15.1) 0.604
   Respiratory disorders, other 12.5 (11.8–13.2) 16.1 (15.2–17.1) <0.001
   Hypothyroidism 17.6 (16.8–18.4) 6.44 (5.83–7.05) <0.001
   Dementia and delirium 13.3 (12.6–14.0) 8.44 (7.75–9.14) <0.001
   Prostatic hypertrophy – 24.6 (23.5–25.7) –
   Dermatitis and eczema 9.80 (9.17–10.4) 10.3 (9.58–11.1) 0.287
   Chronic renal failure 8.19 (7.60–8.77) 12.3 (11.5–13.1) <0.001
   Glaucoma 10.4 (9.76–11.1) 8.61 (7.91–9.30) <0.001
   Deafness, hearing loss 9.57 (8.94–10.2) 9.17 (8.45–9.89) 0.419
   AMI† 5.84 (5.34–6.34) 13.8 (12.9–14.6) <0.001
   Chronic ulcer of the skin 10.2 (9.58–10.9) 7.40 (6.74–8.04) <0.001
   Hematologic disorders, other 7.94 (7.37–8.52) 9.43 (8.70–10.2) 0.002
   Asthma 10.6 (10.0–11.3) 4.69 (4.16–5.22) <0.001
   Low back pain 6.54 (6.01–7.06) 6.10 (5.50–6.69) 0.280
   Gout 2.70 (2.35–3.04) 10.5 (9.75–11.3) <0.001
Continued
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Characteristics Women (n=8488) Men (n=6182) P value
   Neurologic disorders, other 6.63 (6.10–7.16) 5.10 (4.55–5.64) <0.001
   Diverticular disease of colon 5.75 (5.25–6.24) 4.82 (4.29–5.35) 0.014
   Other endocrine disorders 5.96 (5.46–6.47) 3.80 (3.32–4.28) <0.001
95% confidence intervals are displayed within brackets. Only comorbidities with a mean prevalence equal to or greater than 5% are 
displayed.
*Defined as having two or more chronic conditions from a list of 114 chronic diagnoses.
†Acute myocardial infarction.
Table 1 Continued
explained because a) both COPD and HF share similar 
symptoms; b) beta- blockers (indicated for HF) and bron-
chodilators (indicated for COPD) have an effect on both 
pathologies; and c) heart congestion alters pulmonary 
function tests, among others. In this regard, a study 
found that congestive heart failure is strongly associated 
with comorbidities that may lead to the misdiagnosis 
and, more specifically, over- diagnosis of COPD in these 
patients.21
Comorbid depression, which was predominantly observed 
in women, presented a prevalence 2–3 times higher than 
that observed in the general population.13 Its prevalence is 
consistent with that reported in the meta- analytic review by 
Rutledge et al,22 where the mean prevalence of depression 
in HF patients was 21.5%. Depression has been associated 
to worse prognosis in patients with cardiovascular disease 
in terms of mortality, hospital admissions and functional 
status.1 However, its role as a potential risk factor for the 
development of HF is less consistent; so far, this has only 
been proven in women and in older patients with systolic 
hypertension.23 The greater prevalence of hypothyroidism 
observed in HF patients compared with that of the popula-
tion aged ≥65 years from the same reference cohort (3.1% 
in men; 12.7% in women)13 could be partially explained by 
the structural and haemodynamic secondary effects of the 
lack of thyroid hormones on the heart. The higher prev-
alence of hypothyroidism observed in women compared 
with men is congruent with the results from the Euro Heart 
Failure Survey II.19
The clinical composition of the multimorbidity patterns 
found in the study and their impact on mortality and 
hospitalisation is discussed below. In general, the number 
and type of patterns obtained in men and women were 
very similar, although their prevalence, composition and 
impact on health outcomes differed moderately.
Cardiovascular pattern
This pattern mainly included cardiac arrhythmia, cardiac 
valve disorders and hematologic disorders (eg, antico-
agulant therapy), as well as chronic renal failure and 
anaemia. Kidney and heart diseases share common 
risk factors and they are interrelated through adaptive 
mechanisms. Moreover, chronic failure of both organs, 
volume overload, increased levels of cytokines, malab-
sorption syndrome, suppression of the bone marrow 
and anticoagulant therapy increase the frequency of 
anaemia in HF patients.24 The presence of these comor-
bidities in the cardiovascular but not in the coronary- 
ischaemic pattern could imply a greater deterioration in 
HF patients suffering from the former pattern. In fact, 
patients presenting the cardiovascular pattern showed 
significantly higher risk of hospitalisation and mortality 
in both sexes. The strong association of this pattern with 
hospitalisation could probably be due to the haemody-
namic dysfunction produced by cardiac arrhythmias 
and anaemia, which often leads to decompensation and 
subsequent hospitalisation.25
respiratory pattern
The absence of a specific respiratory pattern in men is 
remarkable, as is the absence of COPD in the rest of patterns, 
considering the acknowledged association between COPD 
and ischaemic heart disease,26 both related to HF, and the 
high prevalence of COPD particularly in men. Ahmad et al27 
found that COPD appeared in several clusters of patients 
with HF, especially in those with higher morbidity burden, 
which also clustered with ischaemic heart disease, cerebro-
vascular disease, smoking and male sex. In our study, COPD 
did not come up as part of any pattern in men, suggesting 
a lack of discriminative power of this disease in terms of 
disease clustering in men with HF. Nevertheless, this pattern 
had the second- highest impact on both mortality and hospi-
talisation in women.
Metabolic pattern
This pattern, which was the most prevalent in both sexes, 
included risk factors present in the so- called metabolic 
syndrome. This pattern has been consistently identified 
across studies carried out in the general population, 
and in 18% of patients with HF, with no gender differ-
ences.28 The fact that only two diseases had to be present 
to assign patients to the metabolic pattern could justify 
its higher prevalence. When this pattern was restricted 
to presenting three or more conditions, its prevalence 
decreased to 21.3% in women and 22.1% in men, which 
is closer to previously published prevalence rates. The 
absence of an association of this pattern with increased 
3- year mortality both in men and women is in line with 
existing literature, probably due to reverse epidemiology 
whereby HF patients with cardiovascular risk factors have 
better prognosis.29
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Table 2 Multimorbidity patterns identified in women with 
heart failure (n=8488). Each pattern is represented by the 
comorbidities and their loading factors in the pattern
Patterns Comorbidities
Loading 
factors
Cardiovascular Cardiac arrhythmia 0.80
  Cardiac valve disorders 0.62
  Cardiovascular disorders, other 0.58
  Hematologic disorders, other 0.52
  Surgical aftercare 0.33
  Cardiomyopathy 0.32
  Chronic renal failure 0.29
Respiratory Respiratory disorders, other 0.47
  Emphysema, chronic bronchitis, 
COPD
0.47
  Asthma 0.42
  Other endocrine disorders 0.37
  Chronic renal failure 0.30
  Surgical aftercare 0.25
Metabolic Diabetic retinopathy 0.74
  Diabetes 0.73
  Obesity 0.40
  Hypertension 0.36
  Disorders of lipid metabolism 0.26
Coronary- 
ischaemic
Acute myocardial infarction 0.76
  Ischaemic heart disease 
(excluding AMI*)
0.66
  Surgical aftercare 0.30
Degenerative Varicose veins of lower 
extremities
0.53
  Arthropathy 0.53
  Cataract, aphakia 0.45
  Osteoporosis 0.34
  Thrombophlebitis 0.29
  Deafness, hearing loss 0.26
  Obesity 0.25
  Hypertension 0.25
Neurovascular Dementia and delirium 0.76
  Chronic ulcer of the skin 0.48
  Cerebrovascular disease 0.41
  Chronic renal failure 0.28
  Respiratory disorders, other 0.25
*Acute myocardial infarction.
Table 3 Multimorbidity patterns identified in men with 
heart failure (n=6182). Each pattern is represented by the 
comorbidities and their loading factors in the pattern
Patterns Comorbidities
Loading 
factors
Cardiovascular Cardiovascular disorders, other 0.66
Cardiac arrhythmia 0.64
Cardiac valve disorders 0.58
Cardiomyopathy 0.55
Surgical aftercare 0.46
Hematologic disorders, other 0.39
Respiratory disorders, other 0.39
Chronic renal failure 0.33
  Iron deficiency, other deficiency 
anemias
0.26
Neurovascular Dementia and delirium 0.54
Generalised atherosclerosis 0.52
Peripheral vascular disease 0.46
Chronic renal failure 0.45
Cerebrovascular disease 0.43
Respiratory disorders, other 0.43
Chronic ulcer of the skin 0.39
  Iron deficiency, other deficiency 
anemias
0.39
Metabolic Obesity 0.71
Diabetes 0.45
Hypertension 0.45
Disorders of lipid metabolism 0.40
  Substance use 0.31
Coronary- 
ischaemic
Ischaemic heart disease (excluding 
AMI*)
0.70
Acute myocardial infarction 0.70
Surgical aftercare 0.36
  Disorders of lipid metabolism 0.36
Degenerative Arthropathy 0.43
Cataract, aphakia 0.42
Deafness, hearing loss 0.39
Glaucoma 0.31
Varicose veins of lower extremities 0.30
Dermatitis and eczema 0.30
  Prostatic hypertrophy 0.26
*Acute myocardial infarction.
Coronary-ischemic pattern
This pattern was, along with the metabolic pattern, one 
of the most consistent patterns from a clinical stand-
point. The evolution from micro- and macro- vascular 
endothelial damage caused by arteriosclerosis to myocar-
dial injury represents a pathophysiological continuum 
underlying this pattern. However, our study could not test 
this hypothesis since the medical history of HF patients 
was unknown. Previous studies have corroborated the 
late appearance of ischaemic heart disease in women with 
diabetes and hypertension, whereas, in men, this condi-
tion appears earlier and in association to myocardial 
infarction and smoking.30 The absence of association with 
3- year mortality may be explained by the effectiveness of 
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Table 4 Prevalence of multimorbidity patterns identified in men (n=6182) and women (n=8488) with heart failure, and adjusted 
associations with hospitalisation and death
Multimorbidity pattern
Prevalence 
(%)
Mean age 
(years) Hospitalisation (OR)* P value Death (HR)† P value
Women
  Cardiovascular 29.9 80.4 1.86 (1.66–2.08) <0.001 1.45 (1.33–1.58) <0.001
  Metabolic 49.9 80.1 1.26 (1.13–1.39) <0.001 1.04 (0.97–1.13) 0.284
  Coronary- ischaemic 6.60 80.7 1.48 (1.23–1.79) <0.001 1.13 (0.99–1.30) 0.061
  Neurovascular 13.6 84.1 1.12 (0.97–1.30) 0.117 1.62 (1.48–1.78) <0.001
  Degenerative 64.0 81.1 1.19 (1.06–1.32) 0.002 0.70 (0.65–0.76) <0.001
  Respiratory 16.9 81.0 1.71 (1.50–1.97) <0.001 1.53 (1.39–1.69) <0.001
Men
  Cardiovascular 43.2 76.8 1.83 (1.62–2.07) <0.001 1.60 (1.46–1.76) <0.001
  Metabolic 49.3 75.3 1.37 (1.22–1.53) <0.001 0.98 (0.90–1.07) 0.695
  Coronary- ischaemic 24.7 76.2 1.25 (1.10–1.43) 0.001 0.99 (0.90–1.09) 0.818
  Neurovascular 22.2 79.9 1.62 (1.41–1.86) <0.001 1.74 (1.58–1.91) <0.001
  Degenerative 29.2 80.2 1.03 (0.91–1.16) 0.687 0.75 (0.68–0.81) <0.001
*OR for having at least one hospitalisation during the following year (compared with not having the pattern).
†HR for all- cause death after 3 years of follow- up (compared with not having the pattern).
Figure 1 Kaplan- Meier survival curves in men (n=6182) and women (n=8488) with heart failure according to the presence of 
different patterns of multimorbidity.
beta- blockers, aldosterone antagonists and angiotensin- 
converting enzyme inhibitors in reducing the risk of 
sudden death and prolonging survival in patients with 
HF,31 although this hypothesis needs further investigation 
based on longer follow- up periods.
neurovascular pattern
This pattern included conditions related to arterioscle-
rotic damage in target organs (ie, kidneys, extremities 
and brain) and thromboembolisms secondary to cardiac 
arrhythmia. The presence of dementia in this pattern 
is not unexpected. The relationship between cognitive 
impairment and HF is well known, and is secondary 
to low cerebral perfusion, atrial fibrillation and brain 
changes consequent to the neuro- hormonal adapta-
tion mechanisms underlying HF.32 Patients with this 
pattern had among the highest risks of 3- year mortality. 
However, the lack of impact on women’s hospitalisation 
risk was unexpected, especially bearing in mind that 
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women suffering from this pattern were considerably 
older.
Degenerative pattern
This pattern, predominantly described in women, 
included degenerative conditions such as arthropathy, 
cataracts, aphakia, and hearing loss. Although this 
pattern would be expected to entail a greater degree 
of dependency than others, in the longitudinal 9- year 
study of Jackson et al,33 the neurological and cardiovas-
cular patterns derived in greater limitations on activities 
of daily living compared with the degenerative pattern 
identified by these authors. The co- occurrence of venous 
disease, thrombophlebitis, osteoporosis and dermatitis in 
this pattern could be conditioned by the physical activity 
restrictions of patients with HF. This pattern was the only 
one associated to a decreased risk of 3- year mortality in 
both men and women, maybe due to the lower clinical 
severity of the conditions conforming it, some of which 
are typical of older age.
Overall, our results reflect the importance of taking 
the complete constellation of diseases that surrounds 
HF into account in both its study and clinical manage-
ment. Comorbidities have been found to cluster simi-
larly in both sexes; however, some relevant differences 
have emerged in the composition of the patterns and its 
impact on health outcomes. Although exploratory, these 
findings may provide important clues on which specific 
comorbidities or disease combinations should be given 
more attention in men and women with HF in order to 
better orient disease prevention and control strategies. 
Specifically, it seems that clinicians should pay particular 
attention to the presence of neurovascular and other 
cardiovascular comorbidities in both men and women, 
and to respiratory diseases in the case of women, to try to 
minimise their impact on health outcomes.
strengths and limitations of the study
The main strength of this study is that it represents a large- 
scale population including real primary and hospital care 
patients with a diagnosis of HF. Moreover, HF comorbidi-
ties were comprehensively studied by using an exhaustive 
list of chronic conditions, and not only the most preva-
lent or severe ones.
One of the main limitations of the study is the cross- 
sectional characterisation of the multimorbidity patterns 
that makes it impossible to understand the chronolog-
ical relationship between the different risk factors and 
chronic diseases. Furthermore, this work is exploratory 
in its approach and methodology. The estimation of the 
effect of multimorbidity patterns on health outcomes did 
not consider the potential confounding role of socioeco-
nomic factors or clinical parameters, like the ejection 
fraction, which were not available in the study cohort. 
Other variables such as lifestyle habits (eg, smoking and 
drinking behaviours) were also unavailable. Diagnoses 
were based on real data extracted from electronic health 
records that were not originally designed for research, 
thus leading to a potential over or under- reporting of 
specific diseases. In this regard, data in the EpiChron 
cohort undergoes continuous quality control check- ups 
that ensure its accuracy and reliability for research 
purposes.
COnClusIOn
This study confirmed that multimorbidity is the norm 
rather than the exception in patients with heart failure, 
and that comorbidities tend to cluster together beyond 
simple chance in the form of multimorbidity patterns that 
impact health outcomes differently in men and women. 
This knowledge could be useful to better understand 
common pathophysiological pathways underlying this 
disease and its comorbidities, and the factors that influ-
ence the prognosis of these patients. Further large scale 
longitudinal studies are encouraged to confirm the exis-
tence of these patterns as well as their differential impact 
on health outcomes.
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